Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBITDA: 2015-2025

Historic EBITDA for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$56.9 million.

  • Spyre Therapeutics' EBITDA fell 2.70% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.6 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$208.6 million for FY2024, which is 13.92% up from last year.
  • Spyre Therapeutics' EBITDA amounted to -$56.9 million in Q3 2025, which was down 35.66% from -$41.9 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' EBITDA peaked at -$6.7 million during Q2 2021, and registered a low of -$159.2 million during Q2 2023.
  • In the last 3 years, Spyre Therapeutics' EBITDA had a median value of -$47.8 million in 2024 and averaged -$54.8 million.
  • As far as peak fluctuations go, Spyre Therapeutics' EBITDA tumbled by 610.19% in 2023, and later soared by 72.28% in 2024.
  • Spyre Therapeutics' EBITDA (Quarterly) stood at -$20.4 million in 2021, then increased by 6.26% to -$19.2 million in 2022, then tumbled by 139.61% to -$45.9 million in 2023, then plummeted by 33.41% to -$61.3 million in 2024, then fell by 2.70% to -$56.9 million in 2025.
  • Its last three reported values are -$56.9 million in Q3 2025, -$41.9 million for Q2 2025, and -$53.6 million during Q1 2025.